Last reviewed · How we verify
Infectious inflammation of intestine — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Metro I.V. In Plastic Container | METRONIDAZOLE | Baxter | Nitroimidazole Antimicrobial [EPC] | 1963-01-01 | ||
| Metronidazol | Metronidazol | University of Oslo | Thioredoxin reductase |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Baxter · 1 drug in Infectious inflammation of intestine
- University of Oslo · 1 drug in Infectious inflammation of intestine
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Infectious inflammation of intestine:
- Infectious inflammation of intestine treatment updates — RSS
- Infectious inflammation of intestine treatment updates — Atom
- Infectious inflammation of intestine treatment updates — JSON
Cite this brief
Drug Landscape (2026). Infectious inflammation of intestine — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infectious-inflammation-of-intestine. Accessed 2026-06-10.
Related
- Infectious inflammation of intestine full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing